The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

11 articles for K Sakata


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3.EBI
Nippon Roche Research Center
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2.EBI
Nippon Roche Research Center
Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1.EBI
Nippon Roche Research Center
Synthesis and evaluation of novel modified¿-lactam prostanoids as EP4 subtype-selective agonists.EBI
Minase Research Institute
Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor.EBI
Mitsubishi Tanabe Pharma Corporation
Design of Novel Series of Antimalarial PMX Inhibitors with Increased Half-Life via Molecular Property Optimization.EBI
Ucb
A lead compound for the development of ABA 8'-hydroxylase inhibitors.EBI
Gifu University
Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.EBI
Minase Research Institute
Beta-D-glycosylamidines: potent, selective, and easily accessible 1-glycosidase inhibitors.EBI
Kyoto University
OXOPYRROLIDINE UREA FPR2 AGONISTSBDB
Bristol-Myers Squibb
Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain.BDB
Mgi Pharma